Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4247469 | 1.00 | BCHE (0.58) | BCHEKMT2AMEN1KDM4EMAPT | |
| SCHEMBL4250735 | 1.00 | BCHE (0.58) | BCHEKMT2AMEN1KDM4EMAPT | |
| Bromide SCHEMBL6181180 | 0.99 | BCHE (0.57) | BCHEKMT2AMEN1KDM4EMAPT | |
| Bromide SCHEMBL6183225 | 0.99 | BCHE (0.57) | BCHEKMT2AMEN1KDM4EMAPT | |
| SCHEMBL6181835 | 0.89 | KMT2A (0.53) | BCHEKMT2AMEN1KDM4C | |
| SCHEMBL9411108 | 0.87 | BCHE (0.64) | BCHEKMT2AMEN1KDM4EMAPT | |
| SCHEMBL31358960 | 0.83 | BCHE (0.60) | BCHEKMT2AMEN1KDM4EMAPT | |
| SCHEMBL26368493 | 0.83 | BCHE (0.60) | BCHEKMT2AMEN1KDM4EMAPT | |
| SCHEMBL12634232 | 0.83 | BCHE (0.60) | BCHEKMT2AKDM4EMAPTKDM4C | |
| SCHEMBL5898915 | 0.82 | ADRB2 (0.64) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058346-A1 | Novel enantiomers of etrahydroisoquinoline derivatives and theirpharmaceutically acceptable salts, their preparations and pharmaceutical compositions | YUN-CHOI HYE-SOOK | 2006-03-16 | — | — | US | claimed |
| EP-1507764-A4 | NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | YUN-CHOI HYE-SOOK (KR) | 2005-06-22 | — | — | EP | claimed |
| EP-1507764-A1 | NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | Yun-Choi, Hye-Sook (KR) | 2005-02-23 | — | — | EP | claimed |
| WO-2003095426-A1 | NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | YUN-CHOI HYE-SOOK (KR) | 2003-11-20 | — | — | WO | claimed |
| US-20090036679-A1 | METHOD FOR RESOLVING ENANTIOMERS FROM RACEMIC MIXTURE HAVING CHIRAL CARBON IN ALPHA POSITION OF NITROGEN | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2009-02-05 | — | — | US | disclosed |
| CN-101336241-A | Method for resolving enantiomers from racemic mixture having chiral carbon in alpha position of nitrogen | CHONG KUN DANG PHARM CORP (KR) | 2008-12-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058346-A1 | Novel enantiomers of etrahydroisoquinoline derivatives and theirpharmaceutically acceptable salts, their preparations and pharmaceutical compositions | TBXA2R, NOS2, TBXAS1 | BCHE 1219/4885KMT2A 3931/4885MEN1 4467/4885 |
| US-20090036679-A1 | METHOD FOR RESOLVING ENANTIOMERS FROM RACEMIC MIXTURE HAVING CHIRAL CARBON IN ALPHA POSITION OF NITROGEN | SRR, NPEPPS, DNPEP | BCHE 11/4885KMT2A 4063/4885MEN1 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.